Merck plans to boost its immunotherapy drugs with tumor-bursting viruses – Chemical & Engineering News
Chemical & Engineering News |
Merck plans to boost its immunotherapy drugs with tumor-bursting viruses
Chemical & Engineering News In fact, Merck has other research programs backed by the hypothesis that Keytruda will work better when used with companion immunotherapy drugs. In early 2017, Merck began Phase I clinical trials testing Keytruda alongside an innate immune system … Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M Merck to Buy Australian Firm to Boost Immunotherapy Pipeline Immunotherapy arms race latest: Merck buys Viralytics for $394m |
